284 related articles for article (PubMed ID: 27486753)
1. Mechanism of BRG1 silencing in primary cancers.
Marquez-Vilendrer SB; Thompson K; Lu L; Reisman D
Oncotarget; 2016 Aug; 7(35):56153-56169. PubMed ID: 27486753
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP; Sanchez-Cespedes M
Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
[TBL] [Abstract][Full Text] [Related]
3. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
[TBL] [Abstract][Full Text] [Related]
4. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
5. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
6. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.
Wong AK; Shanahan F; Chen Y; Lian L; Ha P; Hendricks K; Ghaffari S; Iliev D; Penn B; Woodland AM; Smith R; Salada G; Carillo A; Laity K; Gupte J; Swedlund B; Tavtigian SV; Teng DH; Lees E
Cancer Res; 2000 Nov; 60(21):6171-7. PubMed ID: 11085541
[TBL] [Abstract][Full Text] [Related]
7. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D
Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055
[TBL] [Abstract][Full Text] [Related]
8. Gene silencing associated with SWI/SNF complex loss during NSCLC development.
Song S; Walter V; Karaca M; Li Y; Bartlett CS; Smiraglia DJ; Serber D; Sproul CD; Plass C; Zhang J; Hayes DN; Zheng Y; Weissman BE
Mol Cancer Res; 2014 Apr; 12(4):560-70. PubMed ID: 24445599
[TBL] [Abstract][Full Text] [Related]
9. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates.
Mei L; Alikhan M; Mujacic I; Parilla M; Antic T
Acta Cytol; 2019; 63(5):438-444. PubMed ID: 31230044
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.
Medina PP; Carretero J; Ballestar E; Angulo B; Lopez-Rios F; Esteller M; Sanchez-Cespedes M
Hum Mol Genet; 2005 Apr; 14(7):973-82. PubMed ID: 15731117
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma.
Endo M; Yasui K; Zen Y; Gen Y; Zen K; Tsuji K; Dohi O; Mitsuyoshi H; Tanaka S; Taniwaki M; Nakanuma Y; Arii S; Yoshikawa T
Liver Int; 2013 Jan; 33(1):105-17. PubMed ID: 23088494
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of BRG1 promote oral cancer development.
Gunduz E; Gunduz M; Ouchida M; Nagatsuka H; Beder L; Tsujigiwa H; Fukushima K; Nishizaki K; Shimizu K; Nagai N
Int J Oncol; 2005 Jan; 26(1):201-10. PubMed ID: 15586241
[TBL] [Abstract][Full Text] [Related]
14. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.
Medina PP; Romero OA; Kohno T; Montuenga LM; Pio R; Yokota J; Sanchez-Cespedes M
Hum Mutat; 2008 May; 29(5):617-22. PubMed ID: 18386774
[TBL] [Abstract][Full Text] [Related]
15. Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells.
Wu Q; Sharma S; Cui H; LeBlanc SE; Zhang H; Muthuswami R; Nickerson JA; Imbalzano AN
Oncotarget; 2016 May; 7(19):27158-75. PubMed ID: 27029062
[TBL] [Abstract][Full Text] [Related]
16. [Chromatin remodeling defects and cancer: the SWI/SNF example].
Bourdeaut F; Bièche I
Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
[TBL] [Abstract][Full Text] [Related]
17. Evf2 lncRNA/BRG1/DLX1 interactions reveal RNA-dependent inhibition of chromatin remodeling.
Cajigas I; Leib DE; Cochrane J; Luo H; Swyter KR; Chen S; Clark BS; Thompson J; Yates JR; Kingston RE; Kohtz JD
Development; 2015 Aug; 142(15):2641-52. PubMed ID: 26138476
[TBL] [Abstract][Full Text] [Related]
18. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.
Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE
Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839
[TBL] [Abstract][Full Text] [Related]
19. Polycomb Repressive Complex 2 Confers BRG1 Dependency on the CIITA Locus.
Abou El Hassan M; Yu T; Song L; Bremner R
J Immunol; 2015 May; 194(10):5007-13. PubMed ID: 25862816
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells.
Watanabe T; Semba S; Yokozaki H
Br J Cancer; 2011 Jan; 104(1):146-54. PubMed ID: 21102582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
